


REMARKS

Currently claims 1-11 are pending. Applicants have attached an abstract on a separate sheet of paper as required by US practice, and have amended the specification for purposes of adding the priority information.

Respectfully submitted,



Michael M. Conger
Attorney for Applicants
Registration No. 43,562

Date: October 11, 2004

GlaxoSmithKline Inc.
Corporate Intellectual Property
Five Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709
Phone: 919-483-2474
Facsimile: 919-483-7988

10/511055

DT04 Mod PCT/PTO 12 OCT 2004

**COMPOSITIONS AND METHODS FOR EVALUATING AND DESIGNING
NUCLEAR RECEPTOR LIGANDS THAT MODULATE CO-REGULATOR
AFFINITY**

Abstract of the Disclosure

Isolated corepressor peptides derived from a nuclear receptor interacting motif of corepressor Nuclear Receptor Corepressor (NCoR) or Silencing Mediator of Retinoid and Thyroid receptors (SMRT) are provided which binds to nuclear receptor ligand binding domains. Methods of using these peptides to evaluating selectivity of a ligand for a nuclear receptor subtype and quantitatively profiling selectivity of a test compound for a nuclear receptor are also provided.